• TransThera annual report for 2025 highlighted progress toward first commercialization, led by China NDA acceptance for lead drug Tinengotinib on Dec. 19, 2025 for previously treated cholangiocarcinoma.
• Global expansion remained central, supported by a registrational Phase III multi-regional trial for Tinengotinib across U.S., EU, U.K., South Korea, Taiwan; enrollment expected to complete in 2026.
• Pipeline breadth increased, with six clinical-stage candidates spanning oncology, inflammatory, cardiometabolic diseases; Tinengotinib programs advanced in prostate cancer, breast cancer, liver cancer.
• Business development accelerated via November 2025 NLRP3 collaboration with Neurocrine Biosciences, carrying potential total value up to USD 881.5 million.
• Management outlook targeted China NDA approval in 2026 for Tinengotinib, with commercialization team buildout planned for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences (Nanjing) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260423-12119759), on April 23, 2026, and is solely responsible for the information contained therein.